Dyadic International, Inc.

Equities

DYAI

US26745T1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
1.59 USD -5.36% Intraday chart for Dyadic International, Inc. -13.35% -1.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024
Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dyadic Says Patrick Lucy Named Board Chair; Joseph Hazelton Appointed COO MT
Dyadic International, Inc. Announces Management Changes CI
Dyadic International, Inc. announced that it has received $6 million in funding CI
Dyadic International, Rabian Collaborate to Develop Rabies Vaccine MT
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa CI
Transcript : Dyadic International, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells CI
Dyadic International, Inc. Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus? CI
Transcript : Dyadic International, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Dyadic International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q2 Revenue $837,159, vs. Street Est of $1.3M MT
Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin CI
Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate CI
Transcript : Dyadic International, Inc., Q1 2023 Earnings Call, May 10, 2023
Dyadic International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Dyadic International, Inc.
More charts
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.59 USD
Average target price
7.5 USD
Spread / Average Target
+371.70%
Consensus
  1. Stock Market
  2. Equities
  3. DYAI Stock
  4. News Dyadic International, Inc.
  5. Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q3 Revenue $879.6M